The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.

The Gross Law Firm issues the following notice to shareholders of Dentsply Sirona Inc. . Shareholders who purchased shares of ...

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech ...

More than three years after Novartis’ plan for a speedy approval for intrathecal Zolgensma was thwarted by an FDA requirement ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...

Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

BUD stock and industry peers are falling after the Surgeon General warned that alcohol consumption is linked to seven types ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.